[1] |
Bundhun PK, Kumari A, Huang F. Differences in clinical features observed between childhood-onset versus adult-onset systemic lupus erythematosus: a systematic review and meta-analysis[J]. Medicine (Baltimore), 2017, 96: e8086.
doi: 10.1097/MD.0000000000008086
|
[2] |
Veiga CS, Coutinho DS, Nakaie CMA, et al. Subclinical pulmonary abnormalities in childhood-onset systemic lupus erythematosus patients[J]. Lupus, 2016, 25: 645-651.
doi: 10.1177/0961203316629554
pmid: 26849883
|
[3] |
Torre O, Harari S. Pleural and pulmonary involvement in systemic lupus erythematosus[J]. Presse Medicale Paris Fr, 2011, 40 (1 Pt 2): e19-e29.
|
[4] |
Carmier D, Marchand-Adam S, Diot P, et al. Respiratory involvement in systemic lupus erythematosus[J]. Rev Mal Respir, 2010, 27: e66-e78.
|
[5] |
Cutolo M, Melsens K, Wijnant S, et al. Nailfold capillaroscopy in systemic lupus erythematosus: a systematic review and critical appraisal[J]. Autoimmun Rev, 2018, 17: 344-352.
doi: S1568-9972(18)30031-4
pmid: 29427827
|
[6] |
Anuardo P, Verdier M, Gormezano NWS, et al. Subclinical pulmonary hypertension in childhood systemic lupus erythematosus associated with minor disease manifestations[J]. Pediatr Cardiol, 2017, 38: 234-239.
doi: 10.1007/s00246-016-1504-6
pmid: 27826712
|
[7] |
Araujo DB, Borba EF, Silva CA, et al. Alveolar hemorrhage: distinct features of juvenile and adult onset systemic lupus erythematosus[J]. Lupus, 2012, 21: 872-877.
doi: 10.1177/0961203312441047
pmid: 22427319
|
[8] |
Mira-Avendano IC, Abril A. Pulmonary manifestations of Sjögren syndrome, systemic lupus erythematosus, and mixed connective tissue disease[J]. Rheum Dis Clin North Am, 2015, 41: 263-277.
doi: 10.1016/j.rdc.2015.01.001
|
[9] |
Campos LMA, Kiss MH, D’Amico EA, et al. Anti-phospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus[J]. Lupus, 2003, 12: 820-826.
pmid: 14667097
|
[10] |
Nigrovic PA. Storm warning: lung disease in systemic juvenile idiopathic arthritis[J]. Arthritis Rheumatol Hoboken NJ, 2019, 71: 1773-1775.
|
[11] |
Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study[J]. Rheumatol Oxf Engl, 2014, 53: 1676-1682.
doi: 10.1093/rheumatology/keu165
|
[12] |
Yunt ZX, Chung JH, Hobbs S, et al. High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: relationship to survival[J]. Respir Med, 2017, 126: 100-104.
doi: S0954-6111(17)30099-9
pmid: 28427540
|
[13] |
Mohd Noor N, Mohd Shahrir MS, Shahid MS, et al. Clinical and high resolution computed tomography characteristics of patients with rheumatoid arthritis lung disease[J]. Int J Rheum Dis, 2009, 12: 136-144.
doi: 10.1111/j.1756-185X.2009.01376.x
pmid: 20374331
|
[14] |
Kimura Y, Weiss JE, Haroldson KL, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis[J]. Arthritis Care Res, 2013, 65: 745-752.
doi: 10.1002/acr.21889
|
[15] |
Saper VE, Chen G, Deutsch GH, et al. Emergent high fatality lung disease in systemic juvenile arthritis[J]. Ann Rheum Dis, 2019, 78: 1722-1731.
doi: 10.1136/annrheumdis-2019-216040
pmid: 31562126
|
[16] |
Zisman DA, McCune WJ, Tino G, et al. Drug-induced pneumonitis: the role of methotrexate[J]. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG, 2001, 18: 243-252.
|
[17] |
侯俊, 闫淯淳, 苏改秀, 等. 抗黑色素瘤分化相关基因蛋白5抗体与幼年皮肌炎间质性肺病严重程度的关系[J]. 中华医学杂志, 2021, 101(33): 2606-2610.
|
[18] |
Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial[J]. Lancet Respir Med, 2016, 4: 708-719.
doi: 10.1016/S2213-2600(16)30152-7
pmid: 27469583
|
[19] |
Robles-Perez A, Dorca J, Castellví I, et al. Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data[J]. Rheumatol Int, 2020, 40: 719-726.
doi: 10.1007/s00296-020-04545-0
pmid: 32157369
|
[20] |
Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis[J]. Ann Rheum Dis, 2017, 76: 1327-1339.
doi: 10.1136/annrheumdis-2016-209909
pmid: 27941129
|
[21] |
Valeur NS, Stevens AM, Ferguson MR, et al. Multimodality thoracic imaging of juvenile systemic sclerosis: emphasis on clinical correlation and high-resolution CT of pulmonary fibrosis[J]. AJR Am J Roentgenol, 2015, 204: 408-422.
doi: 10.2214/AJR.14.12461
|
[22] |
Lin Y, Yi Q, Cheng D. Rapid progressive interstitial lung disease as initial manifestation of primary Sjögren’s syndrome: a case report[J]. Int J Clin Exp Med, 2014, 7: 5904-5908.
|
[23] |
Burdt MA, Hoffman RW, Deutscher SL, et al. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings[J]. Arthritis Rheum, 1999, 42: 899-909.
doi: 10.1002/1529-0131(199905)42:5<899::AID-ANR8>3.0.CO;2-L
|
[24] |
Hetlevik SO, Flatø B, Rygg M, et al. Long-term outcome in juvenile-onset mixed connective tissue disease: a nationwide Norwegian study[J]. Ann Rheum Dis, 2017, 76: 159-165.
doi: 10.1136/annrheumdis-2017-eular.3226
|
[25] |
Vegh J, Szodoray P, Kappelmayer J, et al. Clinical and immunoserological characteristics of mixed connective tissue disease associated with pulmonary arterial hypertension[J]. Scand J Immunol, 2006, 64: 69-76.
pmid: 16784493
|